The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
Authors:
Open Access
- 17 May 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (30) , 49773-49782
Abstract
The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLCKeywords
This publication has 57 references indexed in Scilit:
- Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clampingJournal of Experimental & Clinical Cancer Research, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome SequencingScience Translational Medicine, 2012
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral BloodClinical Cancer Research, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsLung Cancer, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node MetastasesClinical Cancer Research, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008